Close

OncoMed Pharma (OMED) Announces Completion of Demcizumab Phase 2 Enrollment as Pancreatic Cancer Treatment

Go back to OncoMed Pharma (OMED) Announces Completion of Demcizumab Phase 2 Enrollment as Pancreatic Cancer Treatment